ARBM-201

ARBM-201 is a first-in-class, small molecule inhibitor that selectively targets pendrin (SLC26A4), an anion-exchanging membrane protein. It is being developed by ArborMed for the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). The drug acts by directly binding to pendrin, thereby inhibiting its anion exchange activity and reducing the export of thiocyanate (SCN-) in inflamed lung tissue. This mechanism leads to decreased production of hypothiocyanite (OSCN-), which is implicated in inflammatory damage during respiratory diseases. Preclinical studies have shown that ARBM-201 reduces pro-inflammatory cytokine levels and improves lung injury parameters in animal models, with high selectivity for SLC26A4 over other similar transporters. The compound demonstrates favorable pharmacokinetics with strong distribution into lung tissue following intravenous administration[1][2][3].